De Novo Pathway: When to Use It and How to Prepare for FDA Success

The De Novo Pathway Is Not a Fallback — It Is a Strategy

Too many device companies treat the De Novo pathway as a consolation prize — something you pursue after a 510(k) gets rejected for lack of a predicate. That framing is wrong, and it costs founders time and money. The De Novo classification process, established under Section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act and codified in 21 CFR Part 860, Subpart D, is a deliberate regulatory tool designed for novel, low-to-moderate risk devices that genuinely have no legally marketed predicate. When used strategically, it does not just clear your device — it creates the predicate that future 510(k) submitters will cite. That is a significant first-mover regulatory advantage.

At ADB Consulting & CRO Inc., we work with startup founders and regulatory affairs teams who are staring down a device that does not fit neatly into the existing classification taxonomy. This post gives you a practical framework for deciding whether De Novo is the right path and how to prepare a submission that actually succeeds.

When Does the De Novo Pathway Apply?

Under 21 CFR 860.260, a De Novo request is appropriate when a device would otherwise be automatically classified as Class III — subject to premarket approval (PMA) — solely because there is no predicate device, not because the device actually poses a high risk. FDA's own De Novo guidance, De Novo Classification Process (Evaluation of Automatic Class III Designation), updated in 2021, frames this as a risk-proportionate reclassification mechanism.

The two submission routes are:

• Direct De Novo: Submit a De Novo request directly to FDA without first receiving a Not Substantially Equivalent (NSE) determination. Available since the 21st Century Cures Act expanded the pathway.
• Post-NSE De Novo: Submit after receiving an NSE decision on a 510(k), typically within 30 days of the determination letter.

In practice, the direct route is almost always preferable. Pursuing a 510(k) you know will receive an NSE wastes three to six months and signals to FDA that your predicate strategy was weak from the start.

The Critical Question: Is Your Device Actually Class I or Class II Risk?

Before drafting a single page of your De Novo request, you need an honest, documented risk-based classification analysis. FDA evaluates De Novo requests against the criteria in 21 CFR 860.7 — the probability of device failure and the severity of harm if failure occurs. Your submission must affirmatively demonstrate that general controls alone, or general controls plus special controls, provide reasonable assurance of safety and effectiveness.

If your device treats a life-threatening condition without alternative therapy, or if the failure mode has irreversible patient consequences with no clinical mitigation, you may be looking at a PMA regardless of novelty. Do not let enthusiasm for the De Novo pathway cause you to understate device risk — FDA will catch it, and the resulting back-and-forth will delay you far more than simply starting with the right pathway.

What a Strong De Novo Submission Looks Like

FDA's 2021 De Novo guidance and the associated submission template outline the core content requirements. Here is where strong submissions differentiate themselves from weak ones:

• Device description and technological characteristics: This section must go beyond your marketing language. Describe the mechanism of action, materials, software architecture (if applicable), and intended use with the precision of an engineering document. Ambiguity here triggers immediate requests for additional information (RFAIs).
• Proposed classification and special controls: This is the heart of the submission. You are not just asking FDA to classify your device — you are proposing the regulatory framework that will govern your device class going forward. Well-drafted special controls, including performance testing standards, labeling requirements, and post-market surveillance conditions, demonstrate regulatory maturity and accelerate FDA review.
• Risk analysis: A rigorous ISO 14971-compliant risk analysis is not optional. Map each hazard to a specific mitigation and show how the proposed special controls address residual risks.
• Performance data: De Novo does not require clinical data in every case, but you need objective evidence that your device performs as intended. Bench testing, biocompatibility per ISO 10993, software validation per IEC 62304 for software-containing devices, and human factors validation per FDA's 2016 guidance are the standard package. Know what FDA expects for your specific device type before designing your test protocols.
• Substantial equivalence is not the standard — but the logic is similar: You are demonstrating that your device is safe and effective at a risk level consistent with Class II, not that it is equivalent to a predicate. Frame your arguments accordingly.

Timeline and Resource Realities

FDA's current goal under MDUFA V is to issue a decision on De Novo requests within 150 days of acceptance. Total calendar time from submission to decision, including any RFAI cycles, often runs 12 to 18 months for complex devices. Budget accordingly. Pre-submission meetings (Q-submissions) under FDA's Q-Sub program are not just encouraged — they are essential for novel device types. A well-prepared Pre-Sub that asks specific, answerable questions can compress your De Novo timeline significantly by resolving classification and testing questions before you invest in your pivotal studies.

Common Mistakes That Sink De Novo Submissions

• Proposing overly broad indications for use that inflate the apparent risk profile
• Submitting without a Pre-Sub meeting for a genuinely novel device type
• Drafting special controls that are too vague to be enforceable — FDA will send it back
• Underestimating software documentation requirements for AI/ML-enabled devices
• Confusing De Novo with a 510(k) in the narrative structure of the submission

Your De Novo Decision Starts with the Right Regulatory Strategy

The De Novo pathway rewards preparation and penalizes improvisation. If your device sits at the intersection of novelty and moderate risk, the question is not whether De Novo is theoretically available — it is whether your submission is built well enough to succeed. That requires a clear classification rationale, well-scoped special controls, and performance data packages designed with FDA's review criteria in mind from day one.

At ADB Consulting & CRO Inc., Andre Butler and the ADB team have guided device companies through De Novo submissions across a range of therapeutic areas and device types. We help you make the go/no-go call early, structure your Pre-Sub strategy, and build submissions that move through FDA review without unnecessary RFAI cycles.

Book a free discovery call today at adbccro.com and let us assess whether De Novo is the right pathway for your device — and what it will take to get there.